---
figid: PMC9684653__fonc-12-1006959-g003
figtitle: Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
organisms:
- Mus musculus
- Rattus norvegicus
- Bikinia letestui
- unidentified
- Homo sapiens
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Danio rerio
pmcid: PMC9684653
filename: fonc-12-1006959-g003.jpg
figlink: /pmc/articles/PMC9684653/figure/f3/
number: F3
caption: Overview of the MDM2–p53 pathway in response to DNA damage. In the absence
  of DNA damage, MDM2 facilitates ubiquitination of p53, tagging it for proteosomal
  degradation. Damage to DNA activates kinases, including ataxia telangiectasia-mutated
  (ATM) kinase, which are responsible for phosphorylating MDM2 and reducing its affinity
  to bind cytosolic p53. Regulators of the MDM2–p53 interaction include the AKT/mTOR
  pathway, ARF, and c-MYC. Downstream transcriptional targets of p53 serve to arrest
  cell-cycle progression and induce cellular apoptosis. Multiple sites of action are
  targeted by MDM2 and MDM2–p53 inhibitors, which decrease p53 degradation in tumors
  with wild-type p53. Created with BioRender.com.
papertitle: Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.
reftext: Raymond S. Traweek, et al. Front Oncol. 2022;12:1006959.
year: '2022'
doi: 10.3389/fonc.2022.1006959
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: dedifferentiated liposarcoma | MDM2 | p53 | targeted therapy | clinical
  trial | small molecular inhibitor
automl_pathway: 0.9499353
figid_alias: PMC9684653__F3
figtype: Figure
redirect_from: /figures/PMC9684653__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9684653__fonc-12-1006959-g003.html
  '@type': Dataset
  description: Overview of the MDM2–p53 pathway in response to DNA damage. In the
    absence of DNA damage, MDM2 facilitates ubiquitination of p53, tagging it for
    proteosomal degradation. Damage to DNA activates kinases, including ataxia telangiectasia-mutated
    (ATM) kinase, which are responsible for phosphorylating MDM2 and reducing its
    affinity to bind cytosolic p53. Regulators of the MDM2–p53 interaction include
    the AKT/mTOR pathway, ARF, and c-MYC. Downstream transcriptional targets of p53
    serve to arrest cell-cycle progression and induce cellular apoptosis. Multiple
    sites of action are targeted by MDM2 and MDM2–p53 inhibitors, which decrease p53
    degradation in tumors with wild-type p53. Created with BioRender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Trp53
  - Bbc3
  - Tsc2
  - Akt1
  - Mtor
  - Mdm2
  - Atm
  - Tpm1
  - Myc
  - Nol3
  - Aurka
  - TP53
  - TP63
  - TP73
  - BBC3
  - TSC2
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - MDM2
  - CDKN2A
  - ATM
  - MYC
  - AURKA
  - Tp53
  - tp53
  - tsc2
  - mtor
  - mdm2
  - atm
  - myca
  - aurka
---
